CO₂ Laser Matrixectomy for Refractory MEK Inhibitor-Induced Paronychia in Children: A Case Series

Area of Science:

• Dermatology
• Oncology
• Pediatric Care

Background:

• Paronychia is a common side effect of MEK inhibitor cancer therapy.
• Current medical treatments for paronychia often yield poor and temporary results.
• This condition can negatively impact patients' quality of life and adherence to treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of CO2 laser matrixectomy for treating paronychia in pediatric patients.
• To assess the long-term outcomes of this surgical intervention in children receiving MEK inhibitor therapy.

Main Methods:

• A retrospective study was conducted at a tertiary center from 2016 to 2026.
• Five pediatric patients with persistent paronychia, unresponsive to conservative treatments, underwent CO2 laser matrixectomy.
• Patient data, including treatment response and complications, were analyzed.

Main Results:

• Complete resolution of paronychia was achieved in all five patients treated with CO2 laser matrixectomy.
• No procedure-related complications were reported.
• Patients successfully continued MEK inhibitor therapy without paronychia recurrence, with favorable outcomes over a mean 4-year follow-up.

Conclusions:

• CO2 laser matrixectomy is a safe and effective treatment for paronychia in children undergoing MEK inhibitor therapy.
• This procedure provides a durable solution, potentially improving treatment adherence and quality of life.
• Further research may support wider adoption of this surgical technique for managing this adverse event.